(Bethesda, Md.) -- Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $3 million agreement with Anthera Pharmaceuticals Inc. to develop a
The multiyear program will support manufacturing and clinical development of the potential enzyme therapy, liprotamase.
Anthera plans to begin a Phase 3
“The Foundation has a long-standing commitment to making liprotamase available to people with CF,” said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. “If successful, this drug has the potential to be an important treatment option for those with the disease.”
Over the past 15 years, the CF Foundation has advocated for the development of liprotamase. It was originally discovered and developed by Altus Pharmaceuticals, with a $25 million commitment from CFFT. In 2011, the FDA said it did not have sufficient clinical trial data to recommend the approval of liprotamase. In 2014, Anthera acquired the potential therapy from Eli Lilly and Company.
About 90 percent of people with cystic fibrosis have pancreatic insufficiency and need to take pancreatic replacement
Anthera is a biopharmaceutical company based in Hayward, Calif.
About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more cystic fibrosis research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a
Laurie Fink, National Director of Media Relations, Cystic Fibrosis Foundation: 301-841-2602; email@example.com